Brokerages Set $32.50 Price Target for SpringWorks Therapeutics (NASDAQ:SWTX)

Shares of SpringWorks Therapeutics (NASDAQ:SWTX) have received an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy recommendation.

Analysts have set a 12-month consensus price objective of $32.50 for the company and are expecting that the company will post ($0.45) earnings per share for the current quarter, according to Zacks. Zacks has also given SpringWorks Therapeutics an industry rank of 82 out of 255 based on the ratings given to its competitors.

A number of equities research analysts have weighed in on the stock. Cowen assumed coverage on shares of SpringWorks Therapeutics in a report on Tuesday. They issued an “outperform” rating on the stock. Goldman Sachs Group assumed coverage on shares of SpringWorks Therapeutics in a report on Tuesday. They issued a “buy” rating and a $37.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on shares of SpringWorks Therapeutics in a report on Tuesday. They issued an “overweight” rating and a $32.00 price objective on the stock. Finally, Wedbush assumed coverage on shares of SpringWorks Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $33.00 price objective on the stock.

In other news, Director Stephen P. Squinto purchased 275,000 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $4,950,000.00. Also, major shareholder Bain Capital Life Sciences Inv purchased 150,000 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $2,700,000.00.

SWTX stock opened at $18.96 on Wednesday. SpringWorks Therapeutics has a 1 year low of $17.66 and a 1 year high of $28.62.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its advanced product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors.

Featured Article: What is the market perform rating?

Get a free copy of the Zacks research report on SpringWorks Therapeutics (SWTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.